polatuzumab vedotin (Polivy)

following a full submission assessed under the orphan medicine process:

polatuzumab vedotin (Polivy®) is accepted for restricted use within NHSScotland.

Indication Under Review: in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

SMC restriction: patients with an International Prognostic Index (IPI) score of 2 to 5
Polatuzumab vedotin, in combination with R-CHP, resulted in a statistically significant improvement in investigator-assessed progression-free survival compared with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP).

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.